Investors

Ambit Biosciences has raised almost $165 million in private funding to date. Our investors are highly regarded in both the venture capital and biotechnology industries.

“We are very committed in our support of Ambit’s research and development efforts. The company has made good progress in furthering the clinical development of all of its clinical assets including its lead compound. Its current pipeline and approach to optimizing and selecting potential new drugs provides Ambit with a competitive edge that we believe is unmatched in the industry.” — Allan Marchington, Partner, Apposite Capital

Investors:

Aisling / Perseus-Soros Biopharmaceutical Fund

Apposite Capital, LLP

Forward Ventures

Genechem

GIMV

Growthworks

Horizon Technology Finance

MedImmune Ventures

OrbiMed Advisors

NovaQuest

Radius Ventures

Roche Venture Fund